Novartis sees hidden value in Xiidra
Novartis will need to boost Xiidra sales to justify the hefty price it has paid, but the Swiss company has form.
Boston buys Vertiflex without investing first
A poor quarter is followed by an acquisition, but is it big enough?
3M manages its wounds with Acelity buy
Acelity falls to 3M, but the conglomerate has taken on a great deal of debt and could see its credit rating fall.
A Nasdaq float is scrapped, but for Poseida that’s great news
The CAR-T company cancels its Nasdaq IPO after securing more in a Novartis-led private financing.
Kiadis moves to reduce reliance on its in-house lead
Perhaps sensing trouble ahead Kiadis diversifies beyond ATIR101 by buying Cytosen, but it is a scientific appointment that will cause real excitement.
Alnylam swaps Regeneron for Sanofi
The RNAi specialist gets an $800m cash injection under a central nervous system tie-up with Regeneron.
Astra shakes hands with Daiichi to take on Roche
UK group bets billions on an Her2 project slated for late-line patients and those with lower expression of the target protein.
Probiodrug wins a market cap-sized grant for Alzheimer’s trial
Probiodrug grabs $15m, but it will need more to fund phase IIb development of its Alzheimer’s candidate, PQ912.
Smith & Nephew buys Osiris and insists it has appetite for more
The UK ortho and woundcare group might yet pounce on Nuvasive.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.